lymphokine-activated killer cells
lymphokine-activated killer cells is a biological therapy with 6 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 2 completed trials
Phase Distribution
Phase Distribution
3
Early Stage
3
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
66.7%
2 of 3 finished
33.3%
1 ended early
0
trials recruiting
6
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery
Biological Therapy and Temozolomide in Treating Patients With Metastatic Melanoma
Fluorouracil and Biological Therapy in Treating Patients With Metastatic Kidney or Colorectal Cancer
Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma
Bispecific Antibody Plus White Blood Cells in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme
Clinical Trials (6)
Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery
Biological Therapy and Temozolomide in Treating Patients With Metastatic Melanoma
Fluorouracil and Biological Therapy in Treating Patients With Metastatic Kidney or Colorectal Cancer
Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma
Bispecific Antibody Plus White Blood Cells in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme
Biological Therapy in Treating Patients With Primary or Advanced Glioma
All 6 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 6